PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2004; 25(03): 15-25
DOI: 10.1055/s-0041-1733079
Original Article

Management of Metastatic Renal Cell Carcinoma

MANJU SENGAR
Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi-110029, India
,
JYOTI WADHWA
Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi-110029, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar aufeRef
 als PDF herunterladen Lizenzen und Reprints
Preview Container


Publikationsverlauf

Artikel online veröffentlicht:
28. März 2022

© 2004. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Landis SH, Murray T, Bolden S, Wingo PA . Cancer statistics. CA Cancer J Clin 1999;49: 8-31.
  • 2 Landis SH, Murray T, Bolden S, Wingo PA . Cancer statistics. CA Cancer J Clin 1999;49: 8-31.
  • 3 Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998;352:1691-6.
  • 4 Bloom HJ. Adjuvant therapy for adenocarcinoma of the kidney: present position and prospects. Br J Urol 1973;45:237-57
  • 5 Motzer RJ, Bander NH, Nan us DM. Renal cell Carcinoma. N Engl J Med 1996;335:865-75.
  • 6 Elson PJ. Prognostic factors in metastatic renal cell carcinoma. In: BudowskiRM, Novick AC, editors. Renal cell carcinoma: molecular biology, immunology, and clinical management. Totowa ( NJ): Humana Press; 2000.pl47-60.
  • 7 Maldazys JD, de Kernion JB. Prognostic factors in metastatic renal cell carcinoma. J Urol 1986;136:376-9
  • 8 Motzer RJ, Mazumdar M, Bacik J,et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530.
  • 9 Kavolius JP, Mastorakos DP, Pavolvich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:2261-6.
  • 10 Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, Dec 15 ;98(12):2566-75.
  • 11 Marcus SG, et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 1993;150(2 pt l):463-6.
  • 12 Rackley R, et al. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 1994; 152(5 pt 1):1399-403.
  • 13 Flanigan RC et al. Nephrectmy followed by interferon alfa-2bcompared with interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med 2001;345(23):1655-9.
  • 14 Franklin JR, et al. Cytoreductive surgery in the management of metastatic renal cell carcinoma : the UCLA experience. Semin Urol Oncol 1996;14 (4):230-6.
  • 15 Mickisch GH, et al. Radical nephrectomy plus interferon alfa based immunotherapy compared with interferon alfa alone in metastatic renal cell carcinoma: a randomized trial. Lancet 2001;358(9286);966-70
  • 16 Wood CG , Huber N, Madsen L, Fortner C, Ramirez E, Swanson DA. Clinical variables that predict survival following cytoreductive nephrectomy for metastatic renal cell carcinoma. J Urol 2001;165(5):184 A.
  • 17 Bennett RT et al. Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995;154(l):32-4.
  • 18 Walther MM, et al. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 1997;158(5):16758.
  • 19 Pantuck AJ, Belldegrun AS, Figlin RA . Nephrectomy and interleukin- 2 for metastatic renal cell carcinoma . N Engl J Med 2001;345(23):1711-2.
  • 20 Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993;20:303-21.
  • 21 Amato RJ. Chemotherapy for renal cell carcinoma . Semin Oncol 2000;27:177-86.
  • 22 Fossa SD, Droz JP, Pavone, Macaluso MM, de- bruyne FJ, Vermeylen K Sylvester R. Vinblastine in metastatic renal cell carcinoma : EORTC phase II trial 30882. The EORTC Genitourinary Group. Eur J Cancer 1992;28A:878-80
  • 23 Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammelza T, et al. Prospective randomized trial of interfern alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859-67.
  • 24 Hrushkey WJ, von Roemeling R , Lanning RM, Rabatin JT. Circadian shaped infusions of floxuridine for progressive metastatic renal cell carcinoma . J Clin Oncol 1990;8:1504-13.
  • 25 Bjarnason GA, Hrushkey WJ, Diasio R , et al . Flat versus circadian modified 14 day infusion of FUDR for advanced renal cell cancer (RCC) : a phase - III study. Proc Am Soc Clin Oncol 1994,13:233.
  • 26 Wenzel C, Locker GJ, Schmidinger M, Mader R, Kramer G , Marberger M, et al. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney Dis 2002;39:48-54.
  • 27 Thodtmann R, Sauter T, Weinknecht S, Weissbach L, et al. A phase II trial of pemetrexed in patients with metastatic renal cell cancer. Invest New Drugs 2003, Aug; 21(3):353-8.
  • 28 Droz JP, Theodore C, Ghosn M, Luper AH, Plot G, De Forgwes, et al. Twelve -year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave -Roussy . Semin Surg Oncol 1988;4:97-9.
  • 29 Rini BI, Vogelzang NJ, Dumas MC, Wade JL, Taber DA, Stabler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion flourouracil in patients with metastatic renal cell cancer. J Clin oncol 2000;18: 2419-26.
  • 30 Bennouna J, Delva R, Gomez F, et al. A phase II study with 5- fluorouracil, folinic acid, and oxaliplatin (FOLFOX- 4 regimen ) in patients with metastatic renal cell carcinoma. Oncology 2003;64:25-7.
  • 31 Milwosky MI, Rosmarin A, Tickoo SK, Papanicolaou N, Nanus DM. Active chemotherapy for collecting duct carcinoma of the Kidney: a case report and review of literature. Cancer 2002;94:111-6.
  • 32 Bangalore N, Bhargava P, Hawkins MJ. Sustained response of sarcomatoid renal cell carcinoma to MAID chemotherapy: a case report and review of literature. Ann Oncol 2001;12:271-4.
  • 33 Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon- Cardo, C et al. Phase I / II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995;13:1958-65.
  • 34 Lippman SM, Parkinson DR, ItriLM, Weber RS, Schanyz SP, Ota DM, et al. 13- cis-retinoic acid and interferon alfa-2a : effective combination therapy for advanced squamous cell carcinoma of the skin . J Natl Cancer Inst 1992;84:235-41.
  • 35 Guo X, Nanus DM, Ruiz A, Rando RR, Bok D, Gudas LH. Reduced levels of retinyl esters and vitamin A in human renal cell cancers. Cancer Res 2001;61;2774-81.
  • 36 Berg WJ, Nanus DM, Leung A, Brown KT, Hutchinson B,Mazumdar M, et al. Up-regulation of retinoic acid receptor beta expression in renal cell cancers in vivo correlates with response to 13- cis -retinoic acid and interferon-alpha-2a. Clin Cancer Res 1999;5:1671-5.
  • 37 Motzer RJ, Schwartz L, Law TM, Murphy BA , Hoffman AD , Albino AP, et al. Interferon alpha -2a and 13- cis- retinoic acid I renal cell carcinoma : antitumour activity in a phase II trial and interaction in vitro. J Clin Oncol 1995;13:1950-7.
  • 38 Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, et al. Phase III trial of interferon alpha with or without 13-cis -retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:2872-80.
  • 39 Atzpodien J, Kirchner H, Bergmann L, Oberneder R, Jonas U, Ganser A. 13-cis- retinoic acid , IFN-alpha, IL-2 and chemotherapy in advanced renal cell carcinoma: results of prospectively randomized trial of the German Cooperative Renal Carcinoma Immunotherapy Group. Proc Am Soc Clin Oncol 1999;18:448a.
  • 40 Goldberg JS, Vargas M, Rosmarin AS et al. Phase I trial of interferon alpha 2b and liposome- encapsulated all- trans retinoic acid in the treatment of patients with advanced renal cell carcinoma. Cancer 2002:95:1220-7.
  • 41 Wilding G, Carducci MA, Hwu W et al. A multicenter phase /-// evaluation of oral bexarotene and interferon alfa-2b combination therapy in patients with advanced renal cell carcinoma( RCC). Proc Am Soc Clin Oncol 2001;763 (abstract)
  • 42 Muss HB, Costanzi JJ, Leavitt R,et al. Recombinant alfa interferon in renal cell carcinoma : a randomized trial of two routes of administration. J Clin Oncol 1987:5:28691.
  • 43 Minasian LM, Motzer RJ, Gluck L,et al. Interferon alfa- 2a in advanced renal cell carcinoma : treatment results and survival in 159 patients with long term follow-up. J Clin Oncol 1993;11:1368-75.
  • 44 Rinehart JJ, Young D, Laforge J, et al. Phase 1/ II trial of interferon-beta-serine in patients with renal cell carcinoma : immunologic and biological effects. Cancer Res 1987;47:2481-5.
  • 45 Gleave ME, Elihilali M, Fradet Y, et al. Interferon gamma-lb compared with placebo in metastatic renal cell carcinoma . N Engl J Med 1998;338:1265-71.
  • 46 Fyfe G, Fischer RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who receive high dose recombinant interleukin therapy. J Cllin Oncol 1995:13:688-96.
  • 47 Figlin RA. Renal cell carcinoma : current status and future plans . Cancer J Sci Am 2000;6(l):52-4.
  • 48 Palmer PA, Atzpodien J, Philip T, et al. A comparison of two modes administration of recombinant interleukin-2 : continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biother 1993;8:123-36.
  • 49 Mcdermott D, Flaherty L, Clark J, et al. A randomized phase III trial of high dose interleukin-2 versus subcutaneous IL-2/ interferon in patients with metastatic renal cell carcinoma. Proc Am soc Clin Oncol 2001;20:685.
  • 50 Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin- 2, recombinant interferon-alfa-2a,or bothin metastatic renal cell carcinoma. N Engl Med 1998;338:1272
  • 51 Bajorin D, Sell KW, Richards JM ,et al. A randomized trial of interleukin-2 plus lymphokine activated killer cells versus interleukin-2 alone in renal cell carcinoma (abstractll06). Proc Am Assoc Cancer Res 1990;31: A1106
  • 52 Koo AS, Tso CL, Pyeret C, et al. Autologous tumour specific cytotoxicity of tumour infiltrating lymphocytes derived from human renal cell carcinoma. J Immunother 1991;10:347
  • 53 Motzer RJ, RakhitA, Thompson JA, et al. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2001;4:257-64.
  • 54 Chang DZ, Olencki T, Budd GT, Peere boom D, Ganapathi R, Osterwalder B, et al. Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cell cancer: toxicity and pharmacokinetics . Cancer Chemother Pharmacol 2001;48:493-8.
  • 55 Ryan CW, Vogelzang NJ, Stadler WM. A phase II trial of intravenous gemcitabine and 5-flourouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma . Cancer 2002 May 15;94(10):2602-9.
  • 56 Ellerhorst JA, Sella, Amato RJ, Tu SM, Millikan RE, Finn LD, et al. Phase II trial of 5-flourouracil , interferon alpha and continuous interleukin-2 for patients with metastatic renal cell carcinoma . Cancer 1997;80:2128-32
  • 57 Negrier S, Caty A, Lesimple T, Douillard JY, Escudier B, Rossi JF, et al. Treatment of patients with metastatic renal cell carcinoma with a combination of interleukin-2 and interferon-alfa with or without flouorouracil. Groupe Francais d’lmmunotherapie Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2000;18:4009-15
  • 58 Ravaud A, Trufflandier N, Ferriere JM, Debled M, et al Subcutaneous interkeukin-2 interferon alpha-2b and 5-fIuorouracil in metastatic renal cell carcinoma as second line treatment after failure of previous immunotherapy : a phase II trial. Br J Cancer 2003 Dec 15;89(12):2213-8.
  • 59 Childs R ,Chernoff A , Contentin N, et al. Regression of metastatic renal cell carcinoma after non-myeloablative allogeneic peripheral- blood stem-cell transplantation. N Engl J Med 2000;343:750-8.
  • 60 Rini B, Zimmerman TM, Stadler W, et al. Allogeneic stem-cell transplantation of renal cell cancer after non myeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002;20(8):2017-24.
  • 61 Bregni M, Dodero A Peccatori J, et al. Non- myeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002;99(11):4234-6.
  • 62 Divgi CR, Bander NH, Scott AM, O’Donoghue JA, Sgouros G, Welt S, et al. Phase 1/ II radioimmunotherapy trial with iodine-131 labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998;4:2729-39.
  • 63 Hinkel A, de riese W, Allelder J, et al. Active specific immunotherapy with an autologous virus modified tumour cell vaccine in human renal cell carcinoma (RCC). Eur J Cancer 1995;3lA:1719-20.
  • 64 Dranoff G, Jaffee e, Lazenby A, et al. Vaccination with irradiated tumour cells engineered to secrete granulocyte-macrophage colony-stimulating factor stimulates potent, specific, long lasting anti tumour immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
  • 65 Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumour cell-dendritic cell hybrids. Nat Med 2000;6:332-6.
  • 66 Su Z, Dannull J, Heiser A, et al. Immunological and clinical responses in metastatic renal cell carcinoma patients vaccinated with tumour RNA transfected dendritic cells. Cancer Res 2003;63:2127-33.
  • 67 Drucker B, Bacik J, Ginsberg M, Marion S, et al. Phase II trial of ZD 1839 (IRESSA) in patients with renal cell carcinoma . Invest New Drugs 2003;21(3):341-5.
  • 68 Weber KL, Doucet M, Price JE. Renal cell carcinoma bone metastasis : epidermal growth factor receptor targeting. Clin Orthop 2003;(415 suppl):S86-94
  • 69 Amato RJ. Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol 2003,46 suppl:S59-65.